Maintain slow breathing to stay in control
Chimeric antigen receptor-modified T-cells in chronic lymphoid leukemia
Tsuchida, T
Disclosures: Eun-Jung Kim: Nothing to Disclose, Dasol Kim: Nothing to Disclose, Banu Akdogan: Nothing to Disclose, Mikkel Holm Vendelbo: Nothing to Disclose, Emilie Munk: Nothing to Disclose, Judith Sailer: Nothing to Disclose, Adriana Filipa Fontes: Nothing to Disclose, Jonas Engler: Nothing to Disclose, Dongsik Park: Nothing to Disclose, Hongjae Lee: Nothing to Disclose, Chunwon Jung: Nothing to Disclose, Byong-Keol Min: Nothing to Disclose, Eok Park: Nothing to Disclose, TaeWon Kim: Nothing to Disclose, Seoyoung Choi: Nothing to Disclose, So-yeon Kim: Nothing to Disclose, Alan DiSpirito: Nothing to Disclose, Thomas Sandahl: Arbormed: Advisor, Orphalan: Speaking and Teaching, Alexion: Grant/Research Support, Univar: Consultant, Ultragenyx: Advisor, Weonbin Im: Nothing to Disclose, So-Young Eun: Nothing to Disclose, Hans Zischka: ArborMed Co., Ltd: Consultant, Valentina Medici: Orphalan: Advisor, Arbormed: Research Grant, Ultragenix: Research Grant, Alexion: Advisor, Vivet: Grant/Research Support 2634 THE IFN-INDUCIBLE MXB LARGE GTPASE ATTENUATES HBV REPLICATION BY ACTIVATING THE RIG-I INNATE IMMUNITY SIGNALING PATHWAY Masazumi Onuki 1 Jun Inoue 1 Masashi Ninomiya 1 Mio Tsuruoka 1 Kosuke Sato 1 Satoko Sawahashi 1 Keishi Ouchi 1 Kengo Watanabe 1 Mark McNiven 2 Atsushi Masamune 1 , 1 Tohoku University Graduate School of Med, 2 Mayo Foundation for Medical Background: Elimination of hepatitis B virus (HBV) from chronically infected patients remains difficult, even though nucleos(t)ide analogs, potent inhibitors of reverse transcription, are widely available
